Cancer testis antigen-derived epitope-specific T cell

Cancer testis antigen-derived epitope-specific T cells are T lymphocytes—either naturally occurring or engineered—that specifically recognize peptides derived from cancer/testis antigens (CTAs) presented on the surface of tumor cells by major histocompatibility complex (MHC) molecules. CTAs such as NY‑ESO‑1, MAGE-A family members, SSX2, DEPDC1, and MPHOSPH1 are typically expressed only in germline tissues like the testis but become aberrantly expressed in various cancers[4]. Because normal somatic tissues do not express these antigens except for immune privileged sites like the testes—which lack HLA class I expression—these antigens represent attractive targets for immunotherapy. Adoptive transfer of CTA-derived epitope-specific T cells has shown clinical efficacy against several cancers including melanoma and synovial sarcoma. These therapies involve isolating or engineering patient’s own T cells to express receptors that target specific CTA epitopes. However, there have been notable safety concerns regarding off-target effects when engineered receptors cross-react with similar peptides present in healthy tissue proteins; fatal neurotoxicity and cardiotoxicity have been reported when targeting certain MAGE family members due to such cross-reactivity[3]. This entry is considered "incorrect" as a canonical target because "Cancer testis antigen-derived epitope-specific T cell" refers not to a single molecular entity but rather describes an entire class of effector immune cells directed against various possible peptide-MHC complexes derived from multiple different CTAs. For structured data purposes it is more appropriate to specify the particular cancer/testis antigen being targeted (e.g., "NY‑ESO‑1", "MAGE-A3") rather than this broad category[2][3].

Other names

CTA-derived epitope-specific T cellCancer/testis antigen-specific T cellCT antigen-targeted T cellNY-ESO-1–specific T cell (for a common example)MAGE-A3–specific T cell (for a common example)

Recognition of cancer testis antigen-derived peptide presented by MHC molecules on tumor cells, leading to targeted immune-mediated killing of cancer cells[2][3].